Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Curis (NASDAQ: CRIS) will report first quarter 2026 financial and operating results on May 12, 2026 at 4:00 p.m. ET and will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.

Rhea-AI Summary

Curis (NASDAQ: CRIS) will report first quarter 2026 financial and operating results on May 12, 2026 at 4:00 p.m. ET and will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.

Dial-in numbers and a live audio webcast are available; a replay will be posted at www.curis.com.

Argus May 6 session

+8.17% close to close Open Argus

Details

News Market Reaction – CRIS

In the May 6 session, CRIS gained 8.17%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.2% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.2% in the session following this news. A strong positive reaction aligns with the pattern that even logistical earnings-date news can coincide with meaningful moves; a prior notice on Mar 12, 2026 saw a -5.93% move. The existing S-3 registering 107,706,700 shares for resale and recent Nasdaq delisting risk underline financing and listing overhangs that could temper sustainability if optimism fades.

Key Figures

Q1 2026 earnings call: 4:00–4:30 p.m. ET on May 12, 2026 Registered resale shares: 107,706,700 shares Cash balance: $5.1 million +5 more

Q1 2026 earnings call

4:00–4:30 p.m. ET on May 12, 2026

Timing for release and conference call/webcast

Registered resale shares

107,706,700 shares

Shares registered on Form S-3 from Jan 2026 financing

Cash balance

$5.1 million

Cash and equivalents as of Dec 31, 2025 (Form 10-K)

PIPE net proceeds

$18.6 million

Net proceeds from January 2026 PIPE financing (Form 10-K)

Shares outstanding

39,978,693 shares

Common shares outstanding as of Mar 20, 2026 (Form 10-K)

Nasdaq bid minimum

$1.00 per share

Minimum bid price under Nasdaq Listing Rule 5550(a)(2)

Days below minimum

30 consecutive business days

Period with bid below $1.00 leading to delist letter

Insider purchase

10,000 shares at $0.5487

Open-market buy by director reported Apr 1, 2026

Previous Conferences,earnings date Reports

1 past event · Latest: Mar 12

Same Type 1 event

1. Mar 12

   Earnings date notice

   24h Move

   -5.9%

   Announced timing for Q4 2025 results and related conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

irak4, flt3

2 terms

irak4 medical

"an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced"

IRAK4 is a protein in immune-system cells that acts like a control knob for inflammation signals, helping the body detect and respond to infections. Drugs that block IRAK4 can dial down excessive inflammation, so IRAK4 is an important target for developing treatments for autoimmune diseases and some cancers; progress or setbacks in IRAK4 drug programs can materially affect the prospects and valuation of companies working in those areas.

flt3 medical

"an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced"

FLT3 is a gene that makes a protein acting like a growth switch for blood-forming stem cells; when that switch is faulty or overactive it can drive certain blood cancers, most notably acute myeloid leukemia. Investors care because drugs that target FLT3 mutations can become important therapies, influencing clinical trial outcomes, regulatory approvals and the future revenues and valuations of biotech companies—think of it as a key control knob whose position can determine a treatment’s market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.

Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). For more information, visit Curis's website at www.curis.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-first-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-12-2026-302763278.html

SOURCE Curis, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Curis (CRIS) release Q1 2026 financial results and hold the conference call?

Curis will release Q1 2026 results on May 12, 2026 at 4:00 p.m. ET. According to Curis, management will host a conference call and webcast the same day at 4:30 p.m. ET for investors and analysts.

How can I join the Curis (CRIS) May 12, 2026 conference call and webcast?

Dial in via (800)-836-8184 U.S. or (646)-357-8785 internationally, or access the live audio webcast. According to Curis, the webcast is available from the investor section of the company website.

Will Curis (CRIS) provide a replay of the May 12, 2026 earnings call and where is it posted?

Yes. A replay of the conference call will be available on the Curis website. According to Curis, the replay can be accessed at www.curis.com after the live event for later listening.

What topics will Curis (CRIS) likely cover during the Q1 2026 call on May 12?

The call will cover first quarter 2026 financial and operating results and related business updates. According to Curis, management will present results and provide an opportunity for investor questions during the webcast and call.

Where can investors find the Curis (CRIS) webcast link for the May 12, 2026 presentation?

Investors can find the live audio webcast link on the company's investor relations webpage. According to Curis, the webcast is accessible from the investor section of the Curis website at the scheduled time.